trending Market Intelligence /marketintelligence/en/news-insights/trending/RxEXLZWS76CsWfsVj6oNsA2 content esgSubNav
In This List

Nuvectra to sell animal research related medical device unit for $5M

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Nuvectra to sell animal research related medical device unit for $5M

Medical device maker Nuvectra Corp. agreed to sell its wholly owned unit, NeuroNexus Technologies Inc., to NEL Group Inc. for $5 million in cash.

NeuroNexus manufactures devices for conducting brain-related clinical research in animals.

NEL Group, which entered the sale agreement with Nuvectra effective Dec. 31, 2018, is affiliated with certain former employees of NeuroNexus.

Plano, Texas-based Nuvectra makes a neurostimulation device to treat chronic intractable pain of the trunk and limbs.

The divestiture will help the company focus resources on its neuromodulation technology, which is being developed to treat overactive bladder and Parkinson's disease, said Nuvectra CEO Scott Drees.